ArticleJournal of gastroenterology2016
Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma.
Article in Journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 72 citations in OpenAlex.
- Biomarker Use in Barrett's Esophagus Surveillance.The American journal of gastroenterology · 2026Review
- A Practical Guide to Incorporating Novel Barrett's Screening/Surveillance Tools into Clinical Practice.Current gastroenterology reports · 2026Review
- MicroRNAs in Esophageal Cancer: Implications for Diagnosis, Progression, Prognosis and Chemoresistance.International journal of molecular sciences · 2026Review
- Nonendoscopic Screening for Barrett's Esophagus: Current Methods, Evidence, and Future Directions.Gastro hep advances · 2026Review
- MiRNA expression analysis from circulating exosomes in Barrett's esophagus patients with visceral obesity.Scientific reports · 2025Article
- Future of image enhanced endoscopy of esophageal adenocarcinoma.Clinical endoscopy · 2025Review
- New Approaches to Screening for Barrett Esophagus.Gastroenterology & hepatology · 2025Article
- Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: theGut · 2025Article
- Cost-effective identification of Barrett's esophagus in the community: A first step towards screening.Journal of gastroenterology and hepatology · 2024Article
- Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.Mayo Clinic proceedings · 2024Review
- Epigenetic Alterations from Barrett's Esophagus to Esophageal Adenocarcinoma.International journal of molecular sciences · 2023Review
- Article
- Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer or precursor lesions.Scientific data · 2022Article
- Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples.EBioMedicine · 2022Article
- Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression.Cancer medicine · 2022Review
- Circulating MicroRNAs in Relation to Esophageal Adenocarcinoma Diagnosis and Survival.Digestive diseases and sciences · 2021Article
- A Physically Active Status Affects the Circulating Profile of Cancer-Associated miRNAs.Diagnostics (Basel, Switzerland) · 2021Article
- Urinary microRNA biomarkers for detecting the presence of esophageal cancer.Scientific reports · 2021Article
- miR-194-5p protects against myocardial ischemia/reperfusion injury via MAPK1/PTEN/AKT pathway.Annals of translational medicine · 2021Article
- Role of Extracellular Vesicles in the Diagnosis and Pathogenesis of Barrett's Esophagus: A Mini-Review.Digestive diseases and sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating microRNAs (miRNAs) have been suggested as novel markers for various diseases. The goal of this pilot study was to identify circulating miRNAs differentially expressed comparing Barrett's esophagus (BE), esophageal adenocarcinoma (EAC), and controls.
methodsMicroRNA expression profiling was performed by qPCR array using plasma from six controls and eight BE and eight EAC patients. Validation was performed by analyzing the expression of six selected miRNAs, by qRT-PCR in 115 plasma samples of controls, BE, and EAC patients. Diagnostic accuracy was evaluated by area under the curve (AUC) analysis.
resultsWe identified three miRNAs that were elevated in EAC and four miRNAs that were elevated in BE. Further validation showed that miRNA-382-5p was significantly increased and miRNA-133a-3p significantly decreased in EAC. miRNA-194-5p and miRNA-451a were significantly increased and miRNA-136-5p significantly decreased in BE versus controls. A combination of three or more miRNAs was found to have a good diagnostic performance in discriminating BE from controls (AUC: 0.832), EAC from controls (AUC: 0.846), and BE from EAC (AUC: 0.797).
conclusionOur data suggest that circulating miRNAs are differentially expressed in BE and EAC. The miRNAs identified may be used for future non-invasive screening of BE and EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.